Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1995 1
1996 1
1997 2
1998 2
2000 1
2001 3
2002 1
2005 1
2010 1
2011 3
2012 1
2013 1
2015 1
2018 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib.
Ielasi L, Sansone V, Granito A, Benevento F, De Lorenzo S, Tovoli F. Ielasi L, et al. Drugs Today (Barc). 2018 Oct;54(10):615-627. doi: 10.1358/dot.2018.54.10.2880176. Drugs Today (Barc). 2018. PMID: 30398482 Review.
Hepatocellular carcinoma (HCC) remains among the neoplastic diseases with the most unfavorable prognosis. Historically, systemic treatments for HCC have been scarce. ...
Hepatocellular carcinoma (HCC) remains among the neoplastic diseases with the most unfavorable prognosis. Historically, systemic trea …
Characteristics and prognosis of patients with thyroglobulin-positive and radioactive iodine whole-body scan-negative differentiated thyroid carcinoma.
Shinohara S, Kikuchi M, Suehiro A, Kishimoto I, Harada H, Hino M, Ishihara T. Shinohara S, et al. Jpn J Clin Oncol. 2015 May;45(5):427-32. doi: 10.1093/jjco/hyv021. Epub 2015 Feb 26. Jpn J Clin Oncol. 2015. PMID: 25724214
OBJECTIVE: The prognosis of differentiated thyroid carcinoma is generally favorable. ...The purpose of this study is to investigate the characteristics and prognosis of differentiated thyroid carcinoma patients who are thyroglobulin positive and scan negative. ...
OBJECTIVE: The prognosis of differentiated thyroid carcinoma is generally favorable. ...The purpose of this study is to investigate t …
Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Otsuki S, Hori R, Shinohara S, Kojima T, Tamaki H, Asato R, Kitamura M, Ichimaru K, Kitani Y, Kumabe Y, Honda K, Tsujimura T, Harada H, Ushiro K, Omori K. Otsuki S, et al. Auris Nasus Larynx. 2022 Oct;49(5):834-844. doi: 10.1016/j.anl.2022.02.006. Epub 2022 Feb 26. Auris Nasus Larynx. 2022. PMID: 35232636
This study aimed to investigate the 2-year long-term outcomes and prognostic factors associated with the response to nivolumab. METHODS: This was a multi-institutional retrospective study. ...Univariate and multivariable analyses were performed to identify the prognosti …
This study aimed to investigate the 2-year long-term outcomes and prognostic factors associated with the response to nivolumab. METHO …
The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
Kim JC, Steinberg GD. Kim JC, et al. J Urol. 2001 Mar;165(3):745-56. J Urol. 2001. PMID: 11176460 Review.
Current molecular markers may also predict the response of carcinoma in situ to therapy. Treatment options available for BCG refractory carcinoma in situ of the bladder include intravesical chemotherapy, combined immuno-chemotherapy and radical cystectomy. ...Some tumor ch …
Current molecular markers may also predict the response of carcinoma in situ to therapy. Treatment options available for BCG refracto …
Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Steinberg G, et al. J Urol. 2000 Mar;163(3):761-7. J Urol. 2000. PMID: 10687972 Clinical Trial.
MATERIALS AND METHODS: A total of 90 patients with recurrent carcinoma in situ after failed multiple prior courses of intravesical therapy, including at least 1 course of BCG, participated in this open label, noncomparative study. ...
MATERIALS AND METHODS: A total of 90 patients with recurrent carcinoma in situ after failed multiple prior courses of intravesical th …
Medical management of patients with refractory carcinoma in situ of the bladder.
Kim JC, Steinberg GD. Kim JC, et al. Drugs Aging. 2001;18(5):335-44. doi: 10.2165/00002512-200118050-00004. Drugs Aging. 2001. PMID: 11392442 Review.
It is ultimately the combined decision of the clinician and patient to determine which course of management is most beneficial....
It is ultimately the combined decision of the clinician and patient to determine which course of management is most beneficial....
Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience.
Nseyo UO, DeHaven J, Dougherty TJ, Potter WR, Merrill DL, Lundahl SL, Lamm DL. Nseyo UO, et al. J Clin Laser Med Surg. 1998 Feb;16(1):61-8. doi: 10.1089/clm.1998.16.61. J Clin Laser Med Surg. 1998. PMID: 9728133
MATERIALS AND METHODS: All 58 patients had failed at least one course of standard intravesical therapy or had contraindication for intravesical chemo- or immunotherapy. ...
MATERIALS AND METHODS: All 58 patients had failed at least one course of standard intravesical therapy or had contraindication for in …
Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ.
Steinberg GD, Smith ND, Ryder K, Strangman NM, Slater SJ. Steinberg GD, et al. Postgrad Med. 2011 May;123(3):28-34. doi: 10.3810/pgm.2011.05.2281. Postgrad Med. 2011. PMID: 21566413
METHODS: Enrolled patients had non-muscle-invasive CIS with or without concurrent papillary disease stage Ta and/or T1 for which papillary tumors had been resected before treatment, and had previously received 2 courses of IVe therapy ( 1 BCG course). Patients recei …
METHODS: Enrolled patients had non-muscle-invasive CIS with or without concurrent papillary disease stage Ta and/or T1 for which papillary t …
Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.
Fouladi M, Stempak D, Gammon J, Klein J, Grant R, Greenberg ML, Koren G, Baruchel S. Fouladi M, et al. Cancer. 2001 Aug 15;92(4):914-23. doi: 10.1002/1097-0142(20010815)92:4<914::aid-cncr1401>3.0.co;2-s. Cancer. 2001. PMID: 11550166 Clinical Trial.
Pharmacokinetic studies were performed after the first dose of amifostine. RESULTS: Twelve patients received 23 courses of ICE and amifostine. Dose-limiting toxicities for amifostine at 740 mg/m(2) were somnolence and anxiety. ...
Pharmacokinetic studies were performed after the first dose of amifostine. RESULTS: Twelve patients received 23 courses of ICE and am …
21 results